2023-06-29 03:12:48 ET
-
CorMedix ( NASDAQ: CRMD ) prices an underwritten public offering of 7.5 million common stock at a public offering price of $4.00 per share and pre-funded warrants to purchase ~2.5M shares of its common stock at a price of $3.999 per pre-funded warrant.
-
The total gross proceeds from the offering are expected to be ~$40 million.
-
Shares are down -18.9% at $4.11 afterhours on Wednesday.
-
Underwriters are granted a 30-day option to purchase up to an additional 1.5M shares of its common stock at the public offering price of $4.00/share.
-
Offering is expected to close on or about July 3, 2023.
-
"Net proceeds from the offering will be used for general corporate purposes, commercialization efforts, research and development, working capital, and general expenditures," the company said in a statement .
-
More on CorMedix:
-
CorMedix resubmits marketing application for lead candidate DefenCath
-
CorMedix receives notice of allowance for US patent application covering lead product DefenCath
For further details see:
CorMedix stock dips on pricing $40M securities offering